Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41232   clinical trials with a EudraCT protocol, of which   6757   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naïve Subjects With Active Radiographic Axial Spondyloarthritis

    Summary
    EudraCT number
    2014-003679-48
    Trial protocol
    CZ   PL  
    Global end of trial date
    06 Sep 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    22 Sep 2018
    First version publication date
    22 Sep 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CNTO1275AKS3001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02437162
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Janssen-Cilag International N.V
    Sponsor organisation address
    Archimedesweg 29, Leiden, Netherlands, 2333 CM
    Public contact
    Clinical Registry group, Janssen-Cilag International N.V, ClinicalTrialsEU@its.jnj.com
    Scientific contact
    Clinical Registry group, Janssen-Cilag International N.V, ClinicalTrialsEU@its.jnj.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    06 Sep 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    06 Sep 2017
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The main objective of the study was to assess the efficacy of ustekinumab in adult subjects with active radiographic axial spondyloarthritis (AxSpA) who were naive to anti-tumor necrosis factor alpha (TNFα) agents, as measured by the reduction in signs and symptoms of radiographic AxSpA.
    Protection of trial subjects
    Safety was evaluated based on adverse events (AEs), clinical laboratory tests, vital sign measurements, physical examinations, electrocardiograms (screening only), concomitant medication review, injection-site reactions, allergic reactions, infections, and tuberculosis (TB) evaluations.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    26 Oct 2015
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Taiwan: 67
    Country: Number of subjects enrolled
    Ukraine: 61
    Country: Number of subjects enrolled
    United States: 5
    Country: Number of subjects enrolled
    Czech Republic: 33
    Country: Number of subjects enrolled
    Korea, Republic of: 29
    Country: Number of subjects enrolled
    Poland: 50
    Country: Number of subjects enrolled
    Russian Federation: 101
    Worldwide total number of subjects
    346
    EEA total number of subjects
    83
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    341
    From 65 to 84 years
    5
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 347 subjects were randomized and 346 subjects were treated (116 subjects to placebo, 116 subjects to ustekinumab 45 mg, and 114 subjects to 90 mg).

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Placebo
    Arm description
    Subjects received placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 16, subjects who met EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) were administered open-label golimumab 50 milligram (mg) SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52. At Week 24 all subjects (with the exception of subjects who qualified for early escape [EE]) were re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing through Week 100.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received placebo subcutaneous (SC) injection.

    Investigational medicinal product name
    Golimumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects who met early escape (EE) criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52.

    Investigational medicinal product name
    Ustekinumab 45 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects (with the exception of subjects who qualified for EE) were re-randomized to receive ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by q12w dosing.

    Investigational medicinal product name
    Ustekinumab 90 mg
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects (with the exception of subjects who qualified for EE) were re-randomized to receive ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing.

    Arm title
    Ustekinumab 45mg
    Arm description
    Subjects received ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 16, subjects who met EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.
    Arm type
    Experimental

    Investigational medicinal product name
    Ustekinumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing.

    Investigational medicinal product name
    Golimumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects who met EE criteria were administered with golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received placebo SC injection to maintain the blind at Week 24.

    Arm title
    Ustekinumab 90mg
    Arm description
    Subjects received ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 16, subjects who meet EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.
    Arm type
    Experimental

    Investigational medicinal product name
    Ustekinumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing.

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects received placebo SC injection to maintain the blind at Week 24.

    Investigational medicinal product name
    Golimumab
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Solution for injection in pre-filled syringe
    Routes of administration
    Subcutaneous use
    Dosage and administration details
    Subjects who met EE criteria were administered with golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.

    Number of subjects in period 1
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Started
    116
    116
    114
    Early escape at Week 16
    26
    21
    14
    Cross over at week 24
    87
    0 [1]
    0 [2]
    Completed
    9
    8
    6
    Not completed
    107
    108
    108
         Death
    -
    1
    -
         Protocol deviation
    -
    1
    -
         Adverse event, non-fatal
    -
    1
    -
         Study discontinued by Sponsor
    93
    98
    97
         Unspecified
    -
    -
    1
         Consent withdrawn by subject
    13
    7
    9
         Lost to follow-up
    1
    -
    1
    Notes
    [1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Subjects who did not met EE criteria at Week 16 were crossed over to Ustekinumab 45 or 90 mg at Week 24.
    [2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.
    Justification: Subjects who did not met EE criteria at Week 16 were crossed over to Ustekinumab 45 or 90 mg at Week 24.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 16, subjects who met EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) were administered open-label golimumab 50 milligram (mg) SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52. At Week 24 all subjects (with the exception of subjects who qualified for early escape [EE]) were re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing through Week 100.

    Reporting group title
    Ustekinumab 45mg
    Reporting group description
    Subjects received ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 16, subjects who met EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.

    Reporting group title
    Ustekinumab 90mg
    Reporting group description
    Subjects received ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 16, subjects who meet EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.

    Reporting group values
    Placebo Ustekinumab 45mg Ustekinumab 90mg Total
    Number of subjects
    116 116 114 346
    Title for AgeCategorical
    Units: subjects
        <65
    115 115 111 341
        >=65
    1 1 3 5
    Title for AgeContinuous
    Units: years
        arithmetic mean (standard deviation)
    38.3 ± 11.35 39.2 ± 10.5 39.5 ± 11.32 -
    Title for Gender
    Units: subjects
        Female
    15 23 14 52
        Male
    101 93 100 294

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 16, subjects who met EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) were administered open-label golimumab 50 milligram (mg) SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52. At Week 24 all subjects (with the exception of subjects who qualified for early escape [EE]) were re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing through Week 100.

    Reporting group title
    Ustekinumab 45mg
    Reporting group description
    Subjects received ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 16, subjects who met EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.

    Reporting group title
    Ustekinumab 90mg
    Reporting group description
    Subjects received ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 16, subjects who meet EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52. At Week 24, subjects received placebo SC injection to maintain the blind.

    Primary: Percentage of Subjects Who Achieved an Assessment of Spondyloarthritis international Society (ASAS) 40 Response at Week 24

    Close Top of page
    End point title
    Percentage of Subjects Who Achieved an Assessment of Spondyloarthritis international Society (ASAS) 40 Response at Week 24
    End point description
    ASAS 40 is defined as improvement from baseline of >= 40 percent (%) and with an absolute improvement from baseline of at least 2 on a 0 to 10 cm scale in at least 3 of the following 4 domains: Patient's global assessment (0 to 10 cm; 0=very well, 10=very poor), Total back pain (0 to 10 cm; 0=no pain, 10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 of which relate to a participant's ability to cope with life), Inflammation (0 to 10 cm; 0=none,10=very severe); and absence of deterioration (no worsening at all from baseline in the remaining domain) from baseline in the potential remaining domain.FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they assigned to regardless of treatment received.
    End point type
    Primary
    End point timeframe
    Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
        number (not applicable)
    28.4
    31.0
    28.1
    Statistical analysis title
    Statistical Analysis 1
    Comparison groups
    Placebo v Ustekinumab 45mg
    Number of subjects included in analysis
    232
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.669
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Percentage difference
    Point estimate
    2.586
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -9.138
         upper limit
    14.31
    Statistical analysis title
    Statistical Analysis 2
    Comparison groups
    Placebo v Ustekinumab 90mg
    Number of subjects included in analysis
    230
    Analysis specification
    Pre-specified
    Analysis type
    superiority
    P-value
    = 0.913
    Method
    Cochran-Mantel-Haenszel
    Parameter type
    Percentage difference
    Point estimate
    -0.646
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    -12.18
         upper limit
    10.887

    Secondary: Percentage of Subjects Who Achieved an ASAS 20 Response at Week 24

    Close Top of page
    End point title
    Percentage of Subjects Who Achieved an ASAS 20 Response at Week 24
    End point description
    ASAS 20 is an improvement from baseline of >= 20% and with an absolute improvement from baseline of at least 1 on a 0 to 10 scale in at least 3 of the following 4 domains: Patient global;Total back pain; BASFI (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of which relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life); Inflammation(0 to 10cm;0=none,10=very severe) and absence of deterioration from baseline (>=20% and worsening of at least 1 on a 0 to 10 scale) in the potential remaining domain. ASAS20 response based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder). FAS population was included. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received.
    End point type
    Secondary
    End point timeframe
    Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
        number (not applicable)
    44.8
    55.2
    50.0
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved at Least a 50 Percent (%) Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24

    Close Top of page
    End point title
    Percentage of Subjects who Achieved at Least a 50 Percent (%) Improvement From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
    End point description
    BASDAI used to measure AS disease severity,consists of 6 questions:fatigue,spinal pain,arthralgia,enthesitis (inflammation of tendons and ligaments),morning stiffness(2questions:duration and severity). Each question to answer 10 cm visual analog scale(VAS),0(none),10(very severe) and for the last question related to morning stiffness duration: 0(0 hours), 10(2 or more hours).Final BASDAI score (ranging 0-10) is average of overall total score. Higher BASDAI score indicates more severe AS symptom. Missing data is imputed using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI](missing responses at post baseline visit imputed as non-responder). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received.
    End point type
    Secondary
    End point timeframe
    Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subejcts
        number (not applicable)
    27.6
    25.0
    25.4
    No statistical analyses for this end point

    Secondary: Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Week 24

    Close Top of page
    End point title
    Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) Total Score at Week 24
    End point description
    BASFI composed 10 questions (each question answered with VAS (0-10 cm) to assess disease severity,including first 8 questions regarding to functional anatomy related activities and remaining 2 questions related to daily activities of AS subjects. Each question is 10cm VAS with value 0(easy), 10(impossible). Final BASFI score mean of 10 scores. BASFI score is average of 10 responses, has minimum value of 0, maximum value 10. Higher BASFI score indicates more severe functional limitations of subject due to AS. Early escape rule was applied (measurement value at Wk20 and Wk 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group were assigned regardless of treatment received. Here 'N' (number of participants analyzed) signifies number of participants who were evaluable for this endpoint.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    88
    95
    99
    Units: Units on a scale
        arithmetic mean (standard deviation)
    -1.85 ± 2.133
    -2.11 ± 2.266
    -2.07 ± 2.502
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved Ankylosing Spondylitis Disease Activity Score-C Reactive Protein (ASDAS-CRP) Inactive Disease (<1.3) at Week 24

    Close Top of page
    End point title
    Percentage of Subjects who Achieved Ankylosing Spondylitis Disease Activity Score-C Reactive Protein (ASDAS-CRP) Inactive Disease (<1.3) at Week 24
    End point description
    ASDAS includes CRP milligram per liter(mg/L); four additional self-reported items (rated on 0-10cm VAS or 0-10 NRS) included total back pain (TBP),duration of morning stiffness (DMS), peripheral pain(PP)/swelling and patient global assessment(PGA). ASDAS calculated as:ASDAS(CRP)=(0.121*TBP)+(0.110*PG)+(0.073*PP/swelling)+(0.058*DMS)+(0.579*Ln(CRP+1), disease activity, TBP, PP/swelling on NRS (0 [normal] to 10 [very severe]), DMS on NRS (0 to10, 0 none, 10 representing duration =>2 hours). Inactive disease(ID) defined as ASDAS score <1.3. ASDAS (CRP) ID is based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responder). FAS included subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they assigned regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
        number (not applicable)
    3.4
    1.7
    2.6
    No statistical analyses for this end point

    Secondary: Change From Baseline in hsCRP Through Week 24

    Close Top of page
    End point title
    Change From Baseline in hsCRP Through Week 24
    End point description
    Change from baseline in hsCRP levels were reported. hsCRP is a sensitive laboratory assay for serum levels of C-Reactive Protein, which is a biomarker of inflammation. Early escape rule was applied (measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Milligrams per decilitre (mg/dL)
    arithmetic mean (standard deviation)
        Week 4 (n=115,116,113)
    -0.10 ± 1.459
    -0.54 ± 1.488
    -0.74 ± 1.839
        Week 8 (n=116,115,114)
    -0.16 ± 1.478
    -0.59 ± 1.236
    -0.66 ± 2.213
        Week 12 (n=115,115,112)
    -0.18 ± 1.571
    -0.80 ± 1.853
    -0.84 ± 2.262
        Week 16 (n=115,116,114)
    -0.11 ± 1.456
    -0.39 ± 3.166
    -0.86 ± 2.261
        Week 20 (n=88,93,99)
    -0.34 ± 1.450
    -0.73 ± 1.792
    -0.79 ± 2.240
        Week 24 (n=87,95,98)
    -0.41 ± 1.737
    -0.72 ± 1.617
    -0.92 ± 2.274
    No statistical analyses for this end point

    Secondary: Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) at Week 16 and 24
    End point description
    Assessment of enthesitis was performed in the following 7 domains: 1) 1st costochondral joint left and right, 2) 7th costochondral joint left and right, 3) posterior superior iliac spine left and right, 4) anterior superior iliac spine left and right, 5) iliac crest left and right, 6) 5th lumbar spinous process and 7) proximal insertion of Achilles tendon left and right. Entheses were scored as either 0 (nontender) or 1 (tender) yielding total MASES ranging from 0 (no tenderness) to 13 (worst possible score; severe tenderness). Early escape rule was applied (measurement value at Wk 20 and Wk 24 was set as missing). Population included subset of FAS with enthesitis at baseline. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    87
    92
    83
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 16 (n=62,59,58)
    -1.53 ± 3.347
    -1.47 ± 3.564
    -1.17 ± 3.101
        Week 24 (n=35,38,44)
    -1.66 ± 3.481
    -1.84 ± 3.301
    -1.73 ± 3.060
    No statistical analyses for this end point

    Secondary: Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Bath Ankylosing Spondylitis Metrology Index (BASMI) at Week 16 and 24
    End point description
    The Bath Ankylosing Spondylitis Metrology Index linear function is a combined index of 5 clinical measurements (performed by the Joint Assessor) which reflect axial mobility in the AS patient. The measurements to assess mobility are: 1)Tragus-to-wall; 2)Modified Schober (lumbar flexion); 3)Cervical rotation angle; 4)Lateral spinal flexion; 5)Intermalleolar distance. The BASMI linear result is the average of the 5 assessments and ranges from 0 to 10. The higher the BASMI score the more severe the patient’s limitation of movement due to their AS. Early escape rule was applied (measurement value was set as missing).FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 16 (n=114,114,111)
    -0.26 ± 1.015
    -0.26 ± 1.044
    -0.17 ± 0.840
        Week 24 (n=87,92,97)
    -0.36 ± 0.943
    -0.37 ± 0.946
    -0.27 ± 0.877
    No statistical analyses for this end point

    Secondary: Change from Baseline in Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) Score at Week 16 and 24

    Close Top of page
    End point title
    Change from Baseline in Ankylosing Spondylitis Quality of Life questionnaire (ASQoL) Score at Week 16 and 24
    End point description
    The ASQoL is a self-administered health-related quality of life (HRQOL) instrument. It consists of 18 items requesting a Yes or No response to questions related to the impact of the disease/condition (including pain) on sleep, mood, motivation, ability to cope, activities of daily living, independence, relationships, and social life. A score of 1 is given to a response of “yes” on each item and all item scores are summed to a total score with a range of 0 to 18. Higher scores indicate worse HRQOL. Early Escape rule was applied (measurement value was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 16 (n=114,116,113)
    -2.61 ± 4.385
    -3.03 ± 4.416
    -2.93 ± 3.954
        Week 24 (n=87,94,98)
    -4.21 ± 4.441
    -4.48 ± 4.808
    -4.31 ± 4.537
    No statistical analyses for this end point

    Secondary: Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 16 and 24
    End point description
    FACIT-Fatigue score calculated according to 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. Subjects scored each item on 5-point scale:0 (Not at all) to 4(Very much). larger participant's response to questions (exception of 2 negatively stated), greater participant's fatigue. All questions, except for 2 negatively stated ones, code was reversed, new score was calculated(4 minus participant's response). Sum of all responses resulted in FACIT-Fatigue score for total possible score of 0 (worst score) to 52 (best score). Early escape rule was applied (measurement value was set as missing).FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 16 (n=114,116,113)
    5.71 ± 9.499
    5.44 ± 9.528
    5.96 ± 9.325
        Week 24 (n=87,94,98)
    8.78 ± 10.472
    7.67 ± 10.348
    8.59 ± 10.597
    No statistical analyses for this end point

    Secondary: Change From Baseline in Norm-Based SF-36 Physical Component Summary (PCS) and SF-36 Mental Component Summary (MCS) at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Norm-Based SF-36 Physical Component Summary (PCS) and SF-36 Mental Component Summary (MCS) at Week 16 and 24
    End point description
    Medical Outcome Study health measure SF-36 questionnaire is well-validated and widely used quality-of-life instrument. It is self-administered survey consists of 8 multi-item scales: The 4 subscales of SF-36 comprises the PCS(physical functioning, role-physical, bodily pain, and general health), 4 subscales of SF-36, MCS score(vitality, social functioning, role-emotional,mental health). PCS and MCS scored from 0 to 100 with higher scores means better health (worst value is 0 and best value is 100), which are scored using norm-based system. Early escape rule was applied (measurement value at W20 and 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        SF-36 PCS; change at Wk16 (n=114,116,114)
    4.09 ± 7.618
    3.66 ± 6.172
    5.17 ± 6.494
        SF-36 PCS; change at Wk 24 (n=87,94,98)
    7.69 ± 8.001
    6.34 ± 6.198
    7.20 ± 7.343
        SF-36 MCS; change at Wk16 (n=114,116,114)
    4.56 ± 9.113
    3.69 ± 9.690
    4.06 ± 9.034
        SF-36 MCS; change at Wk 24 (n=87,94,98)
    5.05 ± 9.758
    4.82 ± 10.841
    5.46 ± 8.911
    No statistical analyses for this end point

    Secondary: Change From Baseline in BASDAI Inflammation Score Through Week 24

    Close Top of page
    End point title
    Change From Baseline in BASDAI Inflammation Score Through Week 24
    End point description
    The BASDAI is used to measure the ankylosing spondylitis (AS) disease severity. It consists of 6 questions: fatigue, spinal pain, arthralgia (joint pain) or swelling, enthesitis (inflammation of tendons and ligaments), and morning stiffness. Each question is an easy to answer 10 centimeter (cm) visual analog scale (VAS), with 0 being none, and 10 being very severe and the last question: 0=0 hours, 10=2 or more hours. Change from baseline in inflammation was assessed by calculating the average of the Last 2 Questions of the BASDAI Concerning Morning Stiffness. Early escape rule was applied (measurement value was set as missing). FAS included subjects who were randomized and received at least one administration of study agent and analyzed based on randomized treatment group assigned regardless treatment received. 'n' signifies number of participants analyzed for this endpoint at specific timepoints.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 4 (n=116,116,114)
    -0.86 ± 1.650
    -1.09 ± 1.748
    -1.25 ± 1.871
        Week 8 (n=116,115,114)
    -1.45 ± 1.970
    -1.80 ± 2.192
    -1.88 ± 2.160
        Week 12 (n=116,115,112)
    -1.63 ± 2.110
    -1.89 ± 2.143
    -1.88 ± 2.110
        Week 16 (n=115,116,114)
    -1.82 ± 2.221
    -1.98 ± 2.394
    -1.97 ± 2.299
        Week 20 (n=86,92,98)
    -2.48 ± 2.200
    -2.61 ± 2.089
    -2.51 ± 2.429
        Week 24 (n=88,95,99)
    -2.64 ± 2.194
    -2.81 ± 2.257
    -2.74 ± 2.592
    No statistical analyses for this end point

    Secondary: Change From Baseline in Composite and Domain Scores of Medical Outcomes Study Sleep Scale (MOS-SS) at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Composite and Domain Scores of Medical Outcomes Study Sleep Scale (MOS-SS) at Week 16 and 24
    End point description
    Sleep problems (SP) assessed using the 12-item MOS-SS, a generic instrument designed to assess 6 dimensions of sleep: Sleep disturbance(SD), Somnolence, Sleep adequacy (SA), Snoring, Awaken short of breath (ASB) or headache, Quantity of sleep(QS)/optimal sleep(OS) during past 4W. 6 dimensions used to generate composite Sleep Problems Index (SPI). Increase in score from baseline represents improvement. SD, snoring, somnolence, ASB, SP index have score ranges 0(no SP) to 100 (greater SP), negative change indicates improvement. SA scored 0 (least SA) to 100 (better SA), positive change indicates improvement. QS is scored 0 (less QS) to 24 (greater QS), positive change indicates improvement. EE rule was applied (measurement value was set as missing). FAS included subjects randomized, received at least one administration of study agent and analyzed as per treatment group assigned regardless treatment received. 'n': number of subjects analyzed for this endpoint at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        W16: sleep disturbance (n=114,116,113)
    3.15 ± 7.103
    4.13 ± 7.815
    2.79 ± 6.233
        W24: sleep disturbance (n=88,94,98)
    4.57 ± 7.335
    5.85 ± 8.991
    4.79 ± 7.232
        W16: somnolence (n=114,116,113)
    3.79 ± 7.996
    2.06 ± 7.901
    2.73 ± 8.525
        W24: somnolence (n=88,94,98)
    4.99 ± 8.019
    3.16 ± 8.612
    4.52 ± 9.131
        W16: sleep adequacy (n=114,116,113)
    1.78 ± 7.713
    1.42 ± 9.301
    1.50 ± 7.851
        W24: sleep adequacy (n=88,94,98)
    3.03 ± 7.245
    1.75 ± 9.148
    3.41 ± 7.689
        W16: snoring (n=114,116,113)
    0.47 ± 7.026
    1.24 ± 5.753
    1.14 ± 6.520
        W24: snoring (n=88,94,98)
    0.86 ± 7.506
    1.21 ± 6.715
    2.64 ± 7.569
        W16:awaken short of breath/headache(n=114,116,113)
    3.93 ± 12.209
    3.66 ± 11.355
    5.53 ± 12.602
        W24:awaken short of breath/headache (n=88,94,98)
    3.48 ± 11.179
    2.76 ± 11.385
    3.97 ± 12.426
        W16: sleep problems index(n=114,116,113)
    3.72 ± 7.341
    3.76 ± 8.160
    3.19 ± 6.695
        W24:sleep problems index(n=88,94,98)
    5.10 ± 7.338
    4.96 ± 8.794
    5.16 ± 7.795
    No statistical analyses for this end point

    Secondary: Change From Baseline in Composite and Domain Scores of Medical Outcomes Study Sleep Scale (MOS-SS)-Quantity of Sleep/Optimal Sleep at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Composite and Domain Scores of Medical Outcomes Study Sleep Scale (MOS-SS)-Quantity of Sleep/Optimal Sleep at Week 16 and 24
    End point description
    Sleep problems were assessed using the 12-item MOS-SS, a generic instrument designed to assess 6 dimensions of sleep: Sleep disturbance, Somnolence, SA, Snoring, Awaken short of breath or headache, QS/OS during past W4. 6 dimensions used to generate composite SPI. SA scored 0 (least SA) to 100 (better SA), positive change mean improvement. QS is scored 0 (less QS) to 24 (greater QS), positive change mean improvement. Single-item QS asks subjects to estimate average number of hours they slept each night during past 4W (0-24h) and transformed into dichotomous OS Score, reported 7 or 8h of sleep considered Optimal. OS is Yes if average hour of sleep is in range of 7-8h. Early escape rule was applied(measurement value was set as missing).FAS: subjects who were randomized, received at least one administration of study agent, analyzed as per treatment group assigned regardless treatment received. 'n': number of subjects analyzed for this endpoint at specific timepoint.
    End point type
    Secondary
    End point timeframe
    Baseline, Week (W) 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Hours
    arithmetic mean (standard deviation)
        Change-W16: QS/OS(n=114,116,113)
    0.15 ± 0.502
    0.06 ± 0.548
    0.04 ± 0.557
        Change-W24: QS/OS(n=88,94,98)
    0.16 ± 0.500
    0.07 ± 0.626
    0.12 ± 0.579
    No statistical analyses for this end point

    Secondary: Percentage of Subjects With at Least a 40% Improvement From Baseline in ASAS 40 Components at Week 24

    Close Top of page
    End point title
    Percentage of Subjects With at Least a 40% Improvement From Baseline in ASAS 40 Components at Week 24
    End point description
    ASAS 40 components included Patient's global assessment (0 to 10cm; 0=very well,10=very poor),total back pain (0 to 10cm; 0=no pain,10=most severe pain), BASFI (self-assessment represented as mean (0 to 10 cm; 0=easy to 10=impossible) of 10 questions, 8 of relate to participant's functional anatomy and 2 relate to participant's ability to cope with everyday life), Inflammation (0 to 10cm;0=none,10=very severe). Percentage of Participants With at least a 40% improvement from baseline in each of the ASAS components was calculated. FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Patients global assessment (n=114,115,113)
    43.0
    35.7
    31.9
        Total back pain (n=114,115,113)
    42.1
    42.6
    38.9
        Function (n=114,115,113)
    32.5
    33.0
    35.4
        Inflammation (n=114,115,113)
    47.4
    36.5
    37.2
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved at Least 50%, 20%, 70% and 90% Improvement From Baseline in BASDAI Through Week 24

    Close Top of page
    End point title
    Percentage of Subjects who Achieved at Least 50%, 20%, 70% and 90% Improvement From Baseline in BASDAI Through Week 24
    End point description
    BASDAI used to measure the AS disease severity. It consists of 6 questions: fatigue, spinal pain, arthralgia (joint pain) or swelling, enthesitis (inflammation of tendons and ligaments), and morning stiffness (2 questions: duration and severity. Higher BASDAI score indicates more severe AS symptom. 20 %,50%, 70%,90% improvement in BASDAI based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responders). FAS included subjects who were randomized and received at least one administration of study agent and analyzed based on randomized treatment group assigned regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4 (20% improvement)
    25.9
    28.4
    35.1
        Week 8 (20% improvement)
    44.8
    45.7
    43.0
        Week 12 (20% improvement)
    47.4
    45.7
    41.2
        Week 16 (20% improvement)
    49.1
    46.6
    48.2
        Week 20 (20% improvement)
    43.1
    51.7
    50.0
        Week 24 (20% improvement)
    47.4
    55.2
    51.8
        Week 4 (50% improvement)
    3.4
    4.3
    5.3
        Week 8 (50% improvement)
    12.9
    12.9
    14.0
        Week 12 (50% improvement)
    19.0
    12.9
    14.0
        Week 16 (50% improvement)
    19.8
    17.2
    18.4
        Week 20 (50% improvement)
    25.9
    17.2
    22.8
        Week 4 (70% improvement)
    0.9
    0.9
    1.8
        Week 8 (70% improvement)
    6.9
    4.3
    5.3
        Week 12 (70% improvement)
    6.9
    6.9
    7.9
        Week 16 (70% improvement)
    10.3
    9.5
    8.8
        Week 20 (70% improvement)
    11.2
    6.9
    10.5
        Week 24 (70% improvement)
    11.2
    11.2
    11.4
        Week 4 (90% improvement)
    0
    0.9
    0
        Week 8 (90% improvement)
    0.9
    0
    1.8
        Week 12 (90% improvement)
    1.7
    0.9
    1.8
        Week 16 (90% improvement)
    1.7
    1.7
    0.9
        Week 20 (90% improvement)
    2.6
    0.9
    1.8
        Week 24 (90% improvement)
    4.3
    1.7
    4.4
    No statistical analyses for this end point

    Secondary: Change From Baseline in BASDAI Total Score Through Week 24

    Close Top of page
    End point title
    Change From Baseline in BASDAI Total Score Through Week 24
    End point description
    BASDAI used to measure the AS disease severity. It consists of 6 questions: fatigue,spinal pain,arthralgia (joint pain) or swelling, enthesitis (inflammation of tendons and ligaments), and morning stiffness (2 questions: duration and severity). Each question is easy to answer 10 cm VAS, 0 being none,10 being very severe and the last question is: 0=0 hours, 10=2 or more hours. Order to give each of 5 symptoms equal weight, mean of 2 questions about morning stiffness added to total of remaining 4 scores,final BASDAI score (ranging 0-10) is the average of the overall total score. Higher BASDAI score indicates more severe AS symptom. Early escape rule was applied (measurement value at Week 20 and Week 24 was set as missing). FAS population was included and analyzed based on randomized treatment group assigned regardless treatment received. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Week 4 (116,116,114)
    -0.83 ± 1.340
    -0.92 ± 1.550
    -0.87 ± 1.632
        Week 8 (n=116,115,114)
    -1.43 ± 1.849
    -1.67 ± 1.984
    -1.49 ± 2.025
        Week 12 (n=116,115,112)
    -1.59 ± 2.073
    -1.64 ± 2.047
    -1.45 ± 2.118
        Week 16 (n=115,116,114)
    -1.67 ± 2.271
    -1.74 ± 2.300
    -1.60 ± 2.276
        Week 20 (n=86,92,98)
    -2.35 ± 2.226
    -2.39 ± 1.922
    -2.20 ± 2.283
        Week 24 (n=88,95,99)
    -2.52 ± 2.262
    -2.56 ± 2.196
    -2.40 ± 2.356
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Who Achieved ASAS 40 Response at Week 4, 8, 12, 16 and 20

    Close Top of page
    End point title
    Percentage of Subjects Who Achieved ASAS 40 Response at Week 4, 8, 12, 16 and 20
    End point description
    ASAS 40 defined as improvement from baseline of >= 40% and with an absolute improvement from baseline of at least 2 on 0 to 10cm scale in at least 3 of following 4 domains: PGA of disease activity (0 to 10cm; 0=very well,10=very poor),TBP(0 to10cm; 0=no pain,10=most severe pain),BASFI (self-assessment represented as mean (0 to10 cm;0=easy to 10=impossible) of 10 questions, 8 of relate to subject's functional anatomy, 2 relate to subject's ability to cope with life), Inflammation (0 to 10cm;0=none,10=very severe); no worsening at all from baseline in remaining domain. ASAS40 based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).FAS population was included and analyzed based on randomized treatment group assigned regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Week 4, 8, 12, 16, and 20
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4 (ASAS 40)
    7.8
    6.9
    8.8
        Week 8 (ASAS 40)
    14.7
    18.1
    19.3
        Week 12 (ASAS 40)
    19.8
    14.7
    18.4
        Week 16 (ASAS 40)
    22.4
    21.6
    22.8
        Week 20 (ASAS 40)
    22.4
    22.4
    28.9
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Who Achieved ASAS 20 Response at Week 4, 8, 12, 16 and 20

    Close Top of page
    End point title
    Percentage of Subjects Who Achieved ASAS 20 Response at Week 4, 8, 12, 16 and 20
    End point description
    ASAS 20 defined as improvement from baseline of >=20% and absolute improvement of 1 on 0 to 10cm in atleast 3 of 4 domains: PGA disease activity 0 to 10cm;0=very well,10=very poor,TBP 0 to10cm; 0=no pain,10=most severe pain, BASFI(self-assessment represented as 0 to 10cm; 0=easy to10=impossible of 10 questions,8 of which relate subject's functional anatomy,2 relate to subject's ability to cope with life),Inflammation(0 to 10cm;0=none,0=very severe);absence of deterioration(>= 20%,worsening of atleast 1 on 0to10cm) from baseline in remaining domain. ASAS20 based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Wk 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder).FAS population was included and analyzed based on randomized treatment group assigned regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Week 4 , 8, 12, 16 and 20
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4
    20.7
    27.6
    29.8
        Week 8
    33.6
    41.4
    42.1
        Week 12
    37.1
    44.8
    39.5
        Week 16
    44.0
    45.7
    43.9
        Week 20
    39.7
    46.6
    49.1
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved Assessment of Spondyloarthritis international Society (ASAS) Partial Remission Through Week 24

    Close Top of page
    End point title
    Percentage of Subjects who Achieved Assessment of Spondyloarthritis international Society (ASAS) Partial Remission Through Week 24
    End point description
    Low level of disease activity was measured by criteria for ASAS partial remission, defined as a value below 2 on a scale of 0 to 10 cm in each of the 4 ASAS domains: patient’s global assessment of disease activity, total back pain, function (BASFI), inflammation. ASAS partial remission response based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received.
    End point type
    Secondary
    End point timeframe
    Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4
    1.7
    0
    0.9
        Week 8
    3.4
    0.9
    3.5
        Week 12
    4.3
    4.3
    3.5
        Week 16
    8.6
    5.2
    2.6
        Week 20
    7.8
    3.4
    6.1
        Week 24
    6.9
    5.2
    6.1
    No statistical analyses for this end point

    Secondary: Percentage of Subjects Who Achieved ASAS 5/6 Response at Week 16 and 24

    Close Top of page
    End point title
    Percentage of Subjects Who Achieved ASAS 5/6 Response at Week 16 and 24
    End point description
    ASAS 5/6 is defined as a >=20% improvement in any 5 of the 6 domains of pain (VAS 0 to 10), patient global (VAS 0 to 10), function (BASFI score), morning stiffness (from BASDAI), hsCRP, and spine mobility (lumbar side flexion). ASAS 5/6 response is based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24),non-responder[NRI] (missing responses at post baseline visit imputed as non-responder). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received.
    End point type
    Secondary
    End point timeframe
    Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 16
    23.3
    29.3
    26.3
        Week 24
    30.2
    35.3
    33.3
    No statistical analyses for this end point

    Secondary: Change From Baseline in Ankylosing Spondylitis Disease Activity Score ASDAS (CRP) Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Ankylosing Spondylitis Disease Activity Score ASDAS (CRP) Through Week 24
    End point description
    ASDAS includes CRP mg/L; 4 additional self-reported items (rated 0-10cm VAS or 0-10 numerical rating scale [NRS]) included are total back pain (TBP), duration of morning stiffness (DMS), peripheral pain/swelling and patient global assessment (PGA). ASDAS scores calculated as: ASDAS(CRP) = (0.121*TBP)+(0.110*PGA) + (0.073*peripheral pain(PP)/swelling)+(0.058* duration of morning stiffness) + (0.579*Ln(CRP+1)). The disease activity, TBP, and PP/swelling on a NRS(0[normal]-10[very severe]and DMS on NRS(0 to 10, 0 being none and 10 representing a duration=>2 hrs). Missing values were imputed using early escape rule (measurement value was set as missing). FAS included subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group assigned to regardless treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 4 (n=113,116,113)
    -0.41 ± 0.705
    -0.52 ± 0.616
    -0.55 ± 0.673
        Change at Week 8 (n=114,115,114)
    -0.62 ± 0.881
    -0.80 ± 0.764
    -0.75 ± 0.875
        Change at Week 12 (n-=113,114,112)
    -0.66 ± 0.957
    -0.87 ± 0.800
    -0.76 ± 0.881
        Change at Week 16 (n=113,116,114)
    -0.67 ± 1.044
    -0.85 ± 0.972
    -0.80 ± 0.926
        Change at Week 20 (n=84,92,98)
    -1.00 ± 1.033
    -1.13 ± 0.844
    -1.01 ± 0.982
        Change at Week 24 (n=85,95,98)
    -1.10 ± 1.088
    -1.19 ± 0.985
    -1.12 ± 1.005
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved ASDAS (CRP) Inactive Disease (<1.3) at Week 4, 8, 12, 16 and 20

    Close Top of page
    End point title
    Percentage of Subjects who Achieved ASDAS (CRP) Inactive Disease (<1.3) at Week 4, 8, 12, 16 and 20
    End point description
    ASDAS includes CRP mg/L; four additional self-reported items (rated on 0-10cm VAS or 0-10 NRS) included are TBP, duration of DMS, peripheral pain(PP)/swelling and PGA. ASDAS calculated:ASDAS(CRP)=(0.121*TBP)+(0.110*PGA) +(0.073*peripheral pain/swelling)+(0.058*DMS)+(0.579*Ln(CRP+1)). The disease activity, TBP,PP/swelling on NRS(0 (normal) to10 (very severe), DMS on NRS (0 to 10, with 0 being none,10 representing duration of =>2h). Clinically improvement in ASDAS defined as decrease from baseline >=1.1. ASDAS (CRP Inactive Disease (<1.3) based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responders). FAS included subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group assigned to regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Week 4, 8, 12, 16, and 20
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4
    0.9
    0
    0
        Week 8
    0.9
    0.9
    2.6
        Week 12
    1.7
    0.9
    0.9
        Week 16
    1.7
    1.7
    2.6
        Week 20
    4.3
    0.9
    2.6
    No statistical analyses for this end point

    Secondary: Percentage of Subjects With ASDAS (CRP) Major Improvement (Decrease >=2.0) Through Week 24

    Close Top of page
    End point title
    Percentage of Subjects With ASDAS (CRP) Major Improvement (Decrease >=2.0) Through Week 24
    End point description
    ASDAS includes CRP mg/L; four additional self-reported items (rated on 0-10cm VAS or 0-10 NRS) included are TBP, duration of DMS, peripheral pain(PP)/swelling and PGA. ASDAS calculated:ASDAS(CRP)=(0.121*TBP)+(0.110*PGA) +(0.073*peripheral pain/swelling)+(0.058*DMS)+(0.579*Ln(CRP+1)). The disease activity, TBP,PP/swelling on NRS(0 (normal) to10 (very severe), DMS on NRS (0 to 10, with 0 being none,10 representing duration of =>2h). Clinically improvement in ASDAS defined as decrease from baseline >=1.1. ASDAS (CRP) major important improvement (decrease >=2.0) based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responders). FAS included subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group assigned to regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4
    2.6
    3.4
    3.5
        Week 8
    6.9
    8.6
    12.3
        Week 12
    8.6
    9.5
    12.3
        Week 16
    10.3
    13.8
    14.0
        Week 20
    7.8
    15.5
    10.5
        Week 24
    13.8
    16.4
    14.9
    No statistical analyses for this end point

    Secondary: Percentage of Subjects who Achieved ASDAS (CRP) Clinically Important Improvement (Decrease >=1.1) Through Week 24

    Close Top of page
    End point title
    Percentage of Subjects who Achieved ASDAS (CRP) Clinically Important Improvement (Decrease >=1.1) Through Week 24
    End point description
    ASDAS includes CRP mg/L; four additional self-reported items (rated on 0-10cm VAS or 0-10 NRS) included are TBP, duration of DMS, peripheral pain(PP)/swelling and PGA. ASDAS calculated:ASDAS(CRP)=(0.121*TBP)+(0.110*PGA) +(0.073*peripheral pain/swelling)+(0.058*DMS)+(0.579*Ln(CRP+1)). The disease activity, TBP,PP/swelling on NRS(0 (normal) to10 (very severe),DMS on NRS (0 to 10,with 0 being none,10 representing duration of =>2h). Clinically improvement in ASDAS defined as decrease from baseline >=1.1. ASDAS (CRP) clinical important improvement (decrease >=1.1) based on imputed data using treatment failure(consider non-responders at and after treatment failure),early escape rules(consider non-responder at Week 20 and 24), NRI(missing responses at post baseline visit imputed as non-responders). FAS included subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group assigned to regardless treatment received.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Percentage of subjects
    number (not applicable)
        Week 4
    16.4
    13.8
    17.5
        Week 8
    26.7
    31.0
    30.7
        Week 12
    28.4
    37.9
    28.1
        Week 16
    32.8
    35.3
    28.1
        Week 20
    29.3
    31.9
    37.7
        Week 24
    37.9
    40.5
    37.7
    No statistical analyses for this end point

    Secondary: Change From Baseline in BASFI Score at Week 4, 8, 12, 16 and 20

    Close Top of page
    End point title
    Change From Baseline in BASFI Score at Week 4, 8, 12, 16 and 20
    End point description
    The BASFI is composed with 10 questions (each question is answered with a visual analogue scale 0-10 cm) to assess the disease severity, including the first 8 questions regarding to functional anatomy related activities and the remaining 2 questions related to daily activities of AS participants. Each question is a 10cm VAS with a value between 0 (easy) and 10 (impossible). The final BASFI score is the mean of the 10 scores. The BASFI score is the average of the 10 responses and has a possible minimum value of 0 and a possible maximum value of 10. Higher BASFI score indicates more severe functional limitations of the participant due to AS. Change from baseline in BASFI score were imputed using early escape rule (measurement value at Week 20 and Week 24 was set as missing).FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received.
    End point type
    Secondary
    End point timeframe
    Baseline , Week 4, 8, 12, 16, and 20
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 4(n=116,116,114)
    -0.77 ± 1.635
    -0.80 ± 1.359
    -0.90 ± 1.524
        Change at Week 8(n=116,115,114)
    -1.13 ± 1.841
    -1.29 ± 1.904
    -1.29 ± 1.841
        Change at Week 12 (n=116,115,112)
    -1.09 ± 2.015
    -1.22 ± 1.854
    -1.34 ± 2.001
        Change at Week 16(n=115,116,114)
    -1.08 ± 2.179
    -1.35 ± 2.113
    -1.43 ± 2.125
        Change at Week 20 (n=86,92,98)
    -1.71 ± 2.160
    -1.94 ± 1.946
    -2.01 ± 2.291
    No statistical analyses for this end point

    Secondary: Change From Baseline in Chest Expansion at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in Chest Expansion at Week 16 and 24
    End point description
    Chest expansion is the difference, in centimeter (cm), between the circumference of the chest in maximal inspiration and maximal expiration. It is measured at the level of the fourth intercostal space in males, and just below the breasts in females. Change from baseline in chest expansion were imputed using early escape rule (measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline , Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: centimeter(cm)
    arithmetic mean (standard deviation)
        Change at Week 16 (n=114,113,111)
    0.43 ± 7.899
    0.20 ± 2.209
    -0.02 ± 2.240
        Change at Week 24(n=87,92,97)
    -0.16 ± 2.370
    0.32 ± 1.939
    -0.21 ± 2.232
    No statistical analyses for this end point

    Secondary: Change From Baseline in Total Back Pain (TBP) and Night Back Pain (NBP) Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Total Back Pain (TBP) and Night Back Pain (NBP) Through Week 24
    End point description
    The total back pain and nighttime back pain was measured on a VAS (0 to 10 cm; 0 = no pain, 10 = most severe pain). Change from baseline in TBP and NBP were imputed using early escape rule (measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: centimeter
    arithmetic mean (standard deviation)
        Change -W4 in TBP (n=116,116,114)
    -1.13 ± 2.019
    -1.15 ± 1.911
    -1.52 ± 1.895
        Change -W4 in NBP (n=116,116,114)
    -1.05 ± 2.270
    -1.25 ± 1.835
    -1.19 ± 2.082
        Change -W8 in TBP (n=116,115,114)
    -1.80 ± 2.190
    -1.78 ± 2.294
    2.20 ± 2.243
        Change -W8 in NBP (n=116,115,114)
    -1.69 ± 2.264
    -1.85 ± 2.122
    -2.01 ± 2.517
        Change -W12 in TBP (n=116,115,112)
    -1.81 ± 2.295
    -1.70 ± 2.218
    -1.84 ± 2.288
        Change -W12 in NBP (n=116,115,112)
    -1.61 ± 2.342
    -1.79 ± 2.127
    -1.76 ± 2.554
        Change -W16 in TBP (n=115,116,114)
    -1.80 ± 2.374
    -1.87 ± 2.465
    -2.07 ± 2.387
        Change -W16 in NBP (n=115,116,114)
    -1.76 ± 2.506
    -2.02 ± 2.541
    -2.05 ± 2.606
        Change -W20 in TBP (n=86,92,98)
    -2.73 ± 2.456
    -2.74 ± 2.088
    -2.69 ± 2.414
        Change -W20 in NBP (n=86,92,98)
    -2.67 ± 2.602
    -2.73 ± 2.246
    -2.83 ± 2.804
        Change -W24 in TBP (n=88,95,99)
    -2.80 ± 2.528
    -2.90 ± 2.389
    -2.77 ± 2.511
        Change -W24 in NBP (n=88,94,99)
    -2.75 ± 2.597
    -2.79 ± 2.367
    -2.68 ± 2.960
    No statistical analyses for this end point

    Secondary: Change From Baseline in Patients Global Assessment (PGA) Scale Score Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Patients Global Assessment (PGA) Scale Score Through Week 24
    End point description
    The Patient’s Global Assessment of Disease Activity is one of the components of ASAS 40. It is measured on a VAS (0 to 10 cm; 0 = very well, 10 = very poor). Change from baseline in PGA scale were imputed using early escape rule (The measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 4, 8, 12, 16, 20 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 4 (n=116,116,114)
    -0.99 ± 1.727
    -1.01 ± 1.677
    -1.21 ± 1.645
        Change at Week 8 (n=116,115,114)
    -1.48 ± 2.086
    -1.60 ± 2.039
    -1.70 ± 2.096
        Change at Week 12 (n=116,115,112)
    -1.52 ± 2.043
    -1.53 ± 2.100
    -1.77 ± 2.088
        Change at Week 16 (n=115,116,114)
    -1.64 ± 2.259
    -1.73 ± 2.564
    -1.77 ± 2.293
        Change at Week 20 (n=86,92,98)
    -2.10 ± 2.272
    -2.17 ± 2.225
    -2.36 ± 2.283
        Change at Week 24 (n=88,95,99)
    -2.37 ± 2.298
    -2.55 ± 2.664
    -2.50 ± 2.379
    No statistical analyses for this end point

    Secondary: Change From Baseline in EQ-5D Index at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in EQ-5D Index at Week 16 and 24
    End point description
    The EuroQol-5 is a five dimensional health state classification. Each dimension is assessed on a 3-point ordinal scale (1=no problems, 2=some problems, 3=extreme problems). The responses to the five EQ-5D dimensions were scored using a utility-weighted algorithm to derive an EQ-5D health status index score between 0 to 1, with 1.00 indicating "full health" and 0 representing dead. Change from baseline in EQ-5D index were imputed using early escape rule (measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (114,116,113)
    0.08 ± 0.138
    0.09 ± 0.154
    0.10 ± 0.139
        Change at Week 24 (n=87,94,98)
    0.12 ± 0.137
    0.12 ± 0.168
    0.13 ± 0.153
    No statistical analyses for this end point

    Secondary: Change From Baseline in EQ-5D VAS at Week 16 and 24

    Close Top of page
    End point title
    Change From Baseline in EQ-5D VAS at Week 16 and 24
    End point description
    European Quality of Life 5 Dimensions (EQ-5D) visual analog scale (VAS) is a 20 centimeter (cm) vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health). A higher score indicates an improvement in health in the Health Status Index. Change from baseline in EQ-5D VAS were imputed using early escape rule (measurement value at Week 20 and Week 24 was set as missing). FAS included all subjects who were randomized and received at least one administration of study agent. Subjects analyzed based on randomized treatment group they were assigned to regardless of treatment received. Here 'n' signifies number of subjects who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (n=114,116,113)
    11.49 ± 20.328
    11.26 ± 23.588
    13.36 ± 22.110
        Change at Week 24 (n=87,94,98)
    17.57 ± 20.251
    13.90 ± 26.132
    16.80 ± 22.181
    No statistical analyses for this end point

    Secondary: Change From Baseline in Berlin Magnetic Resonance Imaging (MRI) Spine Score at Week 24

    Close Top of page
    End point title
    Change From Baseline in Berlin Magnetic Resonance Imaging (MRI) Spine Score at Week 24
    End point description
    The study used MRI with fat-saturating techniques such as short tau inversion recovery (STIR) to look for the presence of bone marrow edema. The Berlin modification of ASspiMRI-a (ASspiMRI-a) scoring technique assesses inflammation in each of the 23 disc vertebral units (DVU), capturing edema and erosion. Scores for each DVU range from 0-3 (0=normal; 1=minor bone marrow edema [less than or equal to 25% of DVU; 3=severe bone marrow edema (more that 50% of DVU)]. The composite score ranges from 0 to 69, with higher scores indicating more severe inflammation. Population included subset of FAS with subjects who did not meet early escape criteria and have both baseline and Week 24 MRI assessments.
    End point type
    Secondary
    End point timeframe
    Baseline and Week 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    23
    18
    26
    Units: Units on a scale
        arithmetic mean (standard deviation)
    -0.48 ± 2.053
    -0.58 ± 2.343
    -1.15 ± 2.32
    No statistical analyses for this end point

    Secondary: Change From Baseline in Percent Work Time Missed Due to AS [Assessed by Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP)] Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Percent Work Time Missed Due to AS [Assessed by Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP)] Through Week 24
    End point description
    WPAI-SHP is 6-item questionnaire used to assess degree to which specified health problem (here AS) affected work attendance, work productivity (WP) and productivity in non-work regular activities. Patients are asked to consider the past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected WP, degree to which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, percent non-work activity impairment due to AS. Computed percentage range for each sub-scale was 0-100, with higher numbers indicating greater impairment, less productivity. FAS population was included. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (67,67,70)
    -3.72 ± 26.092
    -2.05 ± 26.625
    -2.06 ± 26.486
        Change at Week 24(n=55,56,62)
    -7.37 ± 16.925
    -4.38 ± 22.562
    -7.07 ± 22.081
    No statistical analyses for this end point

    Secondary: Change From Baseline in Percent Impairment While Working Due to AS (Assessed by WPAI-SHP) Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Percent Impairment While Working Due to AS (Assessed by WPAI-SHP) Through Week 24
    End point description
    WPAI-SHP is 6-item questionnaire used to assess degree to which specified health problem (here AS) affected work attendance, work productivity (WP) and productivity in non-work regular activities. Patients are asked to consider the past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected WP, degree to which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, percent non-work activity impairment due to AS. Computed percentage range for each sub-scale was 0-100, with higher numbers indicating greater impairment, less productivity. FAS population was included. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (n= 67, 67, 70)
    -16.87 ± 25.359
    -5.97 ± 21.607
    -17.57 ± 20.032
        Change at Week 16 (n= 55, 56, 62)
    -22.00 ± 21.892
    -13.57 ± 22.758
    -19.68 ± 22.973
    No statistical analyses for this end point

    Secondary: Change From Baseline in Percent Overall Work Impairment Due to AS (Assessed by WPAI-SHP) Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Percent Overall Work Impairment Due to AS (Assessed by WPAI-SHP) Through Week 24
    End point description
    WPAI-SHP is 6-item questionnaire used to assess degree to which specified health problem (here AS) affected work attendance, work productivity (WP) and productivity in non-work regular activities. Patients are asked to consider the past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected WP, degree to which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, percent non-work activity impairment due to AS. Computed percentage range for each sub-scale was 0-100, with higher numbers indicating greater impairment, less productivity. FAS population was included. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (67, 67, 70)
    -16.03 ± 26.281
    -6.64 ± 23.976
    -17.48 ± 20.811
        Change at Week 16 (55, 56, 62)
    -21.98 ± 21.042
    -14.64 ± 24.300
    -20.54 ± 24.271
    No statistical analyses for this end point

    Secondary: Change From Baseline in Percent non Work Activity Impairment Due to AS (Assessed by WPAI-SHP) Through Week 24

    Close Top of page
    End point title
    Change From Baseline in Percent non Work Activity Impairment Due to AS (Assessed by WPAI-SHP) Through Week 24
    End point description
    WPAI-SHP is 6-item questionnaire used to assess degree to which specified health problem (here AS) affected work attendance, work productivity (WP) and productivity in non-work regular activities. Patients are asked to consider the past 7 days prior to each questionnaire day. Questionnaire asks: current employment status, hours worked, hours missed from work for any reason other than AS, hours missed from work due to AS, degree to which AS affected WP, degree to which AS affected non-work regular activities. 4 component scores were then calculated: percent work time missed due to AS; percent impairment while working due to AS, percent overall work impairment due to AS, percent non-work activity impairment due to AS. Computed percentage range for each sub-scale was 0-100, with higher numbers indicating greater impairment, less productivity. FAS population was included. Here 'n' signifies number of participants who were analyzed at each specified timepoint, for each arm, respectively.
    End point type
    Secondary
    End point timeframe
    Baseline, Week 16 and 24
    End point values
    Placebo Ustekinumab 45mg Ustekinumab 90mg
    Number of subjects analysed
    116
    116
    114
    Units: Units on a scale
    arithmetic mean (standard deviation)
        Change at Week 16 (n= 114, 116, 113)
    -14.74 ± 23.013
    -13.45 ± 21.833
    -17.52 ± 22.101
        Change at Week 24 (n= 87, 94, 98)
    -21.72 ± 23.288
    -21.49 ± 23.825
    -21.73 ± 22.339
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Approximately 2 years
    Adverse event reporting additional description
    The safety analysis set included all participants who received at least 1 (partial or complete) administration of study agent, i.e., the treated population. Adverse events were reported according to the treatment they actually received, regardless of the treatments they are randomized to.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.0
    Reporting groups
    Reporting group title
    Placebo
    Reporting group description
    Subjects received placebo subcutaneous (SC) injection at Weeks 0, 4, and 16. At Week 16, subjects who met EE criteria were administered open-label golimumab 50 milligram (mg) SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52. At Week 24 all subjects (with the exception of subjects who qualified for early escape [EE]) were re-randomized to receive either ustekinumab 45 or 90 milligram (mg) SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing through Week 100.

    Reporting group title
    Placebo to Golimumab
    Reporting group description
    Subjects randomized to placebo SC who met early escape criteria and received golimumab from Week 16; adverse events are counted from early escape onward.

    Reporting group title
    Placebo to Ustekinumab 45mg
    Reporting group description
    Subjects randomized to placebo SC and then rerandomized to receive ustekinumab 45 mg at Week 24; adverse events are counted from crossover onward.

    Reporting group title
    Placebo to Ustekinumab 90mg
    Reporting group description
    Subjects randomized to placebo SC and then rerandomized to receive ustekinumab 90 mg at Week 24; adverse events are counted from crossover onward.

    Reporting group title
    Ustekinumab 45mg Only
    Reporting group description
    Subjects received ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by every 12 week dosing, with the last administration of study agent at Week 100. At Week 16, subjects who met EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.

    Reporting group title
    Ustekinumab 45mg to Golimumab
    Reporting group description
    Subjects randomized to ustekinumab 45 mg SC who met early escape criteria and received golimumab from Week 16; adverse events are counted from early escape onward.

    Reporting group title
    Ustekinumab 90mg Only
    Reporting group description
    Subjects received ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100. At Week 16, subjects who meet EE criteria were administered open-label golimumab 50 mg SC administrations at Week 16 and q4w thereafter through Week 52.

    Reporting group title
    Ustekinumab 90mg to Golimumab
    Reporting group description
    Subjects randomized to ustekinumab 90 mg SC who met early escape criteria and received golimumab from Week 16; adverse events are counted from early escape onward.

    Serious adverse events
    Placebo Placebo to Golimumab Placebo to Ustekinumab 45mg Placebo to Ustekinumab 90mg Ustekinumab 45mg Only Ustekinumab 45mg to Golimumab Ustekinumab 90mg Only Ustekinumab 90mg to Golimumab
    Total subjects affected by serious adverse events
         subjects affected / exposed
    2 / 116 (1.72%)
    0 / 26 (0.00%)
    2 / 44 (4.55%)
    2 / 43 (4.65%)
    3 / 116 (2.59%)
    3 / 21 (14.29%)
    2 / 114 (1.75%)
    0 / 14 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    1
    0
    0
         number of deaths resulting from adverse events
    Injury, poisoning and procedural complications
    Back Injury
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    1 / 21 (4.76%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    Concussion
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ligament Sprain
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Muscle Strain
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 2
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Subdural Haematoma
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    1 / 114 (0.88%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Benign Salivary Gland Neoplasm
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    1 / 21 (4.76%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Facial Paralysis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    1 / 116 (0.86%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Ischaemic Stroke
         subjects affected / exposed
    1 / 116 (0.86%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Vertebrobasilar Insufficiency
         subjects affected / exposed
    1 / 116 (0.86%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Eye disorders
    Ocular Hypertension
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    1 / 43 (2.33%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Uveitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    1 / 21 (4.76%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Calculus Urinary
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    1 / 43 (2.33%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Hepatobiliary disorders
    Cholelithiasis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Intervertebral Disc Disorder
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    1 / 116 (0.86%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Osteoarthritis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    1 / 116 (0.86%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Appendicitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    1 / 114 (0.88%)
    0 / 14 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Placebo Placebo to Golimumab Placebo to Ustekinumab 45mg Placebo to Ustekinumab 90mg Ustekinumab 45mg Only Ustekinumab 45mg to Golimumab Ustekinumab 90mg Only Ustekinumab 90mg to Golimumab
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    15 / 116 (12.93%)
    4 / 26 (15.38%)
    3 / 44 (6.82%)
    0 / 43 (0.00%)
    24 / 116 (20.69%)
    7 / 21 (33.33%)
    26 / 114 (22.81%)
    4 / 14 (28.57%)
    Investigations
    Alanine Aminotransferase Increased
         subjects affected / exposed
    6 / 116 (5.17%)
    2 / 26 (7.69%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    8 / 116 (6.90%)
    2 / 21 (9.52%)
    6 / 114 (5.26%)
    0 / 14 (0.00%)
         occurrences all number
    6
    2
    1
    0
    8
    2
    6
    0
    Aspartate Aminotransferase Increased
         subjects affected / exposed
    3 / 116 (2.59%)
    2 / 26 (7.69%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    8 / 116 (6.90%)
    3 / 21 (14.29%)
    3 / 114 (2.63%)
    0 / 14 (0.00%)
         occurrences all number
    4
    2
    0
    0
    8
    3
    3
    0
    Musculoskeletal and connective tissue disorders
    Ankylosing Spondylitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    1
    Fasciitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Metabolism and nutrition disorders
    Hyperglycaemia
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    3 / 116 (2.59%)
    0 / 21 (0.00%)
    1 / 114 (0.88%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    3
    0
    1
    1
    Infections and infestations
    Acute Sinusitis
         subjects affected / exposed
    0 / 116 (0.00%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    1 / 114 (0.88%)
    1 / 14 (7.14%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    1
    Influenza
         subjects affected / exposed
    1 / 116 (0.86%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    2 / 116 (1.72%)
    0 / 21 (0.00%)
    0 / 114 (0.00%)
    1 / 14 (7.14%)
         occurrences all number
    1
    0
    0
    0
    2
    0
    0
    1
    Respiratory Tract Infection Viral
         subjects affected / exposed
    2 / 116 (1.72%)
    0 / 26 (0.00%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    0 / 116 (0.00%)
    0 / 21 (0.00%)
    6 / 114 (5.26%)
    0 / 14 (0.00%)
         occurrences all number
    2
    0
    0
    0
    0
    0
    6
    0
    Upper Respiratory Tract Infection
         subjects affected / exposed
    2 / 116 (1.72%)
    1 / 26 (3.85%)
    0 / 44 (0.00%)
    0 / 43 (0.00%)
    3 / 116 (2.59%)
    2 / 21 (9.52%)
    4 / 114 (3.51%)
    0 / 14 (0.00%)
         occurrences all number
    2
    1
    0
    0
    6
    2
    4
    0
    Viral Upper Respiratory Tract Infection
         subjects affected / exposed
    5 / 116 (4.31%)
    1 / 26 (3.85%)
    1 / 44 (2.27%)
    0 / 43 (0.00%)
    9 / 116 (7.76%)
    2 / 21 (9.52%)
    11 / 114 (9.65%)
    0 / 14 (0.00%)
         occurrences all number
    6
    1
    1
    0
    9
    2
    14
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    04 Aug 2015
    The main reason of this amendment was to included the following changes: a subset of subjects was to be enrolled in an MRI substudy to explore changes in the Berlin MRI spine score during treatment, an additional chemistry assessment at Week 28 was added, clarification on the informed consents for the microbiome and MRI substudies were made, only subjects participating in the MRI substudy were to undergo MRI assessments, and some minor editorial changes. The Sponsor intended to enroll up to 10% of the study population with total spinal ankyloses.
    16 Feb 2016
    The main reason of this amendment was to included the following changes: radiographic progression was added as an efficacy related secondary objective for the study, change in length of the study from Week 64 to Week 112 for subjects who did not meet EE criteria and continued treatment. Subjects who reached Week 64 had the opportunity to decide their participation in the study extension. The added radiographic evaluations (x-ray of cervical and lumbar spine) were to be conducted during the study at baseline and at Week 100, and minor editorial changes.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The study was discontinued since neither dose achieved the study's primary or major secondary endpoints.
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA